Fred Hutch Cancer Center | Strategic Alliance Partners

May 14, 2021

Andrew Coveler, MD, discusses the potential clinical implications of positive data with NUC-3373 in metastatic colorectal cancer.

April 23, 2021

Mazyar Shadman, MD, discusses the emergence of third-generation BTK inhibitors in chronic lymphocytic leukemia.

April 21, 2021

Patients with cancer who have contracted COVID-19 trend towards having high disease severity and mortality, especially among those with select demographic and clinical characteristics, with certain chemotherapy regimens contributing towards a high all-cause mortality.

April 14, 2021

Brian Till, MD, discusses the safety and efficacy of lisocabtagene maraleucel compared with other products under exploration in patients with mantle cell lymphoma.

April 13, 2021

Andrew Coveler, MD, discusses the toxicity profile of NUC-3373 in metastatic colorectal cancer.

April 07, 2021

Mazyar Shadman, MD, discusses considerations for BTK inhibitors in the treatment of patients with chronic lymphocytic leukemia.

April 06, 2021

Brian Till, MD, discusses the utility of brexucabtagene autoleucel in mantle cell lymphoma.

March 18, 2021

Jerald Radich, MD, highlights the role minimal residual disease in acute myeloid leukemia, how different technological advanced have increased the application of MRD-based strategies, and ongoing efforts that are being made to address remaining questions.

March 16, 2021

Brian Till, MD, discusses the potential durability of brexucabtagene autoleucel in mantle cell lymphoma.

March 04, 2021

Brian Till, MD, discusses the potential to utilize CAR T-cell therapy earlier in the treatment of patients with mantle cell lymphoma.

February 18, 2021

Mazyar Shadman, MD, discusses the potential utility of LOXO-305 in chronic lymphocytic leukemia.

February 15, 2021

Dr. Schilsky highlights key milestones in his career with ASCO, Dr. Gralow speaks to the short- and long-term goals she plans to accomplish in her new role at ASCO, and both speak to their thoughts on the future of cancer care.

February 12, 2021

Andrew Coveler, MD, discusses the rationale to evaluate NUC-3373 in metastatic colorectal cancer.

February 02, 2021

Julie R. Gralow, MD, discusses the integration of precision medicine into oncology.

January 07, 2021

Elena Gabriela Chiorean, MD, discusses the role of genetic testing in pancreatic cancer.

January 04, 2021

Julie Gralow, MD, discusses exciting research in HER2-positive breast cancer.

December 21, 2020

Michael Schweizer, MD, discusses the rationale for the phase 3 CARD trial in metastatic castration-resistant prostate cancer.

December 07, 2020

Michael Schweizer, MD, discusses the role of olaparib in patients with non–BRCA-mutant metastatic castration-resistant prostate cancer.

November 23, 2020

Daniel W. Lin, MD, discusses the limitations of currently available biomarkers in prostate cancer.

October 28, 2020

Christina Baik, MD, MPH, highlights the evolving role of EGFR inhibition in the NSCLC space.